OHSU

IRB #

IRB00006918

Title

RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

Principal Investigator

Peter Andersen

Study Purpose

The purpose of this study is to determine if adding the chemotherapy agent cetuximab to radiation therapy will be beneficial in patients with head and neck cancer who have recently been treated surgically.

Medical Condition(s)

Squamous cell carcinoma (SCC) of the head and neck that has been or will be treated surgically.

Eligibility Criteria

Adults diagnosed with head and neck cancer. Surgery must be completed within 7 weeks of enrollment. Blood work, tumor scans, and tumor tissue testing will be performed and reviewed to determine eligibility.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Treatment in this study will last 6 to 11 weeks.

Minors Included

No

Contact

Will Stott, Senior Research Associate
E-mail: stottw@ohsu.edu
Phone: 503-418-9235

Sponsor

Radiation Therapy Oncology Group (RTOG)

Recruitment End

12/31/2016

Compensation Provided

No


Go Back